Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS-MAPK signaling, a proposed key mechanism of resistance to KRAS G12C inhibition in CRC. Here, we report on divarasib plus cetuximab …
Continua a leggere

Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been …
Continua a leggere

Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting
Purpose: Only one-half of deficient mismatch repair (d-MMR) metastatic colorectal cancers (mCRC) demonstrate durable responses to immune checkpoint inhibitors (ICIs). Given preclinical data indicating that liver metastases sequester activated CD8+ T cells from systemic circulation, we examined clinical outcome by metastatic site …
Continua a leggere

Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy
Background: The immune response has important clinical value in colorectal cancer (CRC) in both prognosis and response to immunotherapy. This study aims to explore tumour immune cell infiltration in relation to clinically well-established molecular markers of CRC. Methods: Multiplex immunohistochemistry and multispectral imaging was used to evaluate tumour infiltration of cytotoxic T cells (CD8+), Th1 cells (T-bet+), T regulatory cells (FoxP3+) …
Continua a leggere

Making Palliative Care a part of your Oncology Practice
I mercoledì dell’oncologia
Webinar , 10 gennaio 2024 dalle 17.00 alle 18.15

Corso per Quality Assurance e Auditor
FAD , 11 gennaio – 18 marzo 2024

Back from San Antonio 2024
Genova, 12 – 13 gennaio 2024

Quali le sfide da affrontare nel Tumore Germinale del testicolo
I mercoledì dell’oncologia
Webinar , 17 gennaio 2024 dalle 17.00 alle 18.15

CONTROVERSIES IN GENITOURINARY TUMORS
Milano, 18 gennaio 2024

Best from San Antonio 2023
Webinar ECM, 25 gennaio 2024

La Ricerca alla Portata del Paziente 3.0
Roma, 26 gennaio 2024

SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2024
Negrar (VR), 26 – 27 gennaio 2024